Reza Zadno Sells 26,423 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) Stock

PROCEPT BioRobotics Co. (NASDAQ:PRCT - Get Free Report) CEO Reza Zadno sold 26,423 shares of the company's stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $97.22, for a total transaction of $2,568,844.06. Following the completion of the sale, the chief executive officer now directly owns 152,762 shares of the company's stock, valued at $14,851,521.64. The trade was a 14.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Reza Zadno also recently made the following trade(s):

• On Wednesday, November 27th, Reza Zadno sold 26,420 shares of PROCEPT BioRobotics stock. The stock was sold at an average price of $97.83, for a total value of $2,584,668.60.
• On Wednesday, November 20th, Reza Zadno sold 26,420 shares of PROCEPT BioRobotics stock. The stock was sold at an average price of $92.57, for a total value of $2,445,699.40.
• On Wednesday, October 30th, Reza Zadno sold 288,461 shares of PROCEPT BioRobotics stock. The shares were sold at an average price of $91.00, for a total value of $26,249,951.00.

PROCEPT BioRobotics Price Performance

PRCT traded up $1.23 on Friday, reaching $94.84. 403,796 shares of the company's stock were exchanged, compared to its average volume of 652,267. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. The stock's fifty day moving average price is $85.25 and its 200-day moving average price is $74.48. PROCEPT BioRobotics Co. has a twelve month low of $36.99 and a twelve month high of $103.81. The stock has a market cap of $4.95 billion, a PE ratio of -48.01 and a beta of 0.99.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its earnings results on Monday, October 28th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.09. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The company had revenue of $58.40 million for the quarter, compared to analyst estimates of $53.30 million. During the same period in the previous year, the business posted ($0.51) EPS. PROCEPT BioRobotics's revenue was up 66.4% on a year-over-year basis. Sell-side analysts expect that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.

Institutional Trading of PROCEPT BioRobotics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Values First Advisors Inc. acquired a new stake in shares of PROCEPT BioRobotics during the third quarter valued at about $27,000. Mark Sheptoff Financial Planning LLC acquired a new stake in PROCEPT BioRobotics in the 2nd quarter valued at approximately $36,000. Quest Partners LLC raised its position in PROCEPT BioRobotics by 2,492.3% in the second quarter. Quest Partners LLC now owns 674 shares of the company's stock valued at $41,000 after purchasing an additional 648 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in PROCEPT BioRobotics during the third quarter worth $64,000. Finally, Canton Hathaway LLC purchased a new position in shares of PROCEPT BioRobotics during the third quarter worth $66,000. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on PRCT. Morgan Stanley initiated coverage on shares of PROCEPT BioRobotics in a research note on Monday. They set an "overweight" rating and a $105.00 price objective for the company. Truist Financial reaffirmed a "buy" rating and issued a $105.00 price objective (up from $95.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, October 30th. Jefferies Financial Group assumed coverage on shares of PROCEPT BioRobotics in a research report on Thursday, November 14th. They set a "hold" rating and a $95.00 target price on the stock. Bank of America raised their target price on shares of PROCEPT BioRobotics from $80.00 to $94.00 and gave the stock a "buy" rating in a report on Thursday, August 22nd. Finally, Wells Fargo & Company reaffirmed an "overweight" rating and set a $112.00 price target on shares of PROCEPT BioRobotics in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $97.86.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.